FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
30/06/2026
Voltar para busca
Dado oficial do USPTO
DELFRANA
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
31
Atualização mais recente
30/06/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5
Data de depósito
09/07/2024
Data de registro
31/03/2026
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
31/03/2026
Última transação
30/06/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
03
Localização do titular
CH
Examinador
WELLS, KELLEY L
Unidade examinadora
M90
Localização atual
FILE REPOSITORY (FRANCONIA)
Titulares e representantes
Titulares
Novartis AG
Representantes
Maury M. Tepper, III Tepper & Eyster, PLLC
Classificação técnica
Classes Nice
Classe 5
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical preparations; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastro-intestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for ophthalmological use; pharmaceutical preparations for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and treatment of allergies; pharmaceutical preparations for the prevention and treatment of bone diseases; pharmaceutical preparations for the prevention and treatment of respiratory diseases and asthma.
Publicações
Histórico de despachos e eventos da marca no USPTO.
31 publicações encontradas
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
31/03/2026
R.PR
REGISTERED-PRINCIPAL REGISTER
31/03/2026
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
26/02/2026
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
11/02/2026
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
11/02/2026
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
10/02/2026
PUBO
PUBLISHED FOR OPPOSITION
10/02/2026
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
04/02/2026
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
16/01/2026
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
09/01/2026
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/01/2026
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
09/01/2026
RFNT
REFUSAL PROCESSED BY IB
29/08/2025
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
12/08/2025
RFRR
REFUSAL PROCESSED BY MPU
12/08/2025
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
12/08/2025
CNRT
NON-FINAL ACTION WRITTEN
11/08/2025
RFWR
NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW
19/01/2025
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
22/12/2024
CNRT
NON-FINAL ACTION WRITTEN
21/12/2024
DOCK
ASSIGNED TO EXAMINER
21/12/2024
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
11/10/2024
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
11/10/2024
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
11/10/2024
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
11/10/2024
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
11/10/2024
MAFR
APPLICATION FILING RECEIPT MAILED
07/10/2024
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
07/10/2024
LIMI
LIMITATION FROM ORIGINAL APPLICATION ENTERED
19/09/2024
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
12/09/2024
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace DELFRANA ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.